Extrapulmonary Neuroendocrine Carcinoma

Extrapulmonary Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

315 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 104
Recruiting: 46
Ph III recruiting: 1
Growth YoY: —
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (50)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07720193	A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC	not yet recruiting	Phase 3	280	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	Sep 1, 2026	clinicaltrials
NCT05078047	Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO)	active not recruiting	Phase 3	646	UNICANCEROTHER	1	Jul 17, 2026